Zibotentan not effective when used alone in treatment of mCRPC

According to a media release this morning from AstraZeneca, the company’s investigational drug zibotentan (also known as ZD4054) was not effective in extending the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) in a randomized, double-blind, placebo-controlled Phase III trial. … READ MORE …

ZD4054 and OGX-011: promise that needs to be confirmed

In the past two days, data has been made available from Phase II trials suggesting the potential of the AstraZeneca endothelin antagonist ZD4054 and Oncogenex’s resistance inhibitor OGX-011 in the treatment of hormone-refractory prostate cancer. … READ MORE …